1α, 25-dihydroxy cholecalciferol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 1α, 25-dihydroxy cholecalciferol
• 英文别名: 1α, 25-dihydroxycholecalciferol；1α,25-dihydroxy cholecalciferol；1α,25-dihydroxy-vitamin D3；1Alpha,25-Dihydroxy-Vitamin D；(1R,3R,5Z)-5-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• 化学式: C₂₇H₄₄O₃
• 分子量: 416.645
• InChiKey: GMRQFYUYWCNGIN-GSMZWGLTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Vitamin D derivative having substituent at 2beta-position
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20020045772A1

  公开（公告）日：2002-04-18

  A steroid intermediate has the formula (II): 1 wherein A denotes alkylene of 2 to 10 carbons; X denotes halogen; R a , R b and R c denote, independently hydrogen or hydroxyl protecting group; and R p , R q , R y and R z are such that R p and R q together form a double bond between the 5-position and the 6-position and R y and R z together form a double bond between the 7-position and the 8-position, or R q and R y together form a double bond between the 6-position and the 7-position and R p and R z are bound to a dienophile capable of protecting conjugated double bonds.

  一种甾体中间体具有公式(II)：1，其中A代表2至10个碳原子的烷基；X代表卤素；Ra、Rb和Rc分别独立表示氢或羟基保护基团；而Rp、Rq、Ry和Rz是这样的，即Rp和Rq共同在5位和6位之间形成一个双键，Ry和Rz共同在7位和8位之间形成一个双键，或者Rq和Ry共同在6位和7位之间形成一个双键，而Rp和Rz则与能保护共轭双键的二烯烃基团结合。
• 3-Desoxy-2-Methylene-Vitamin D Analogs and Their Uses
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20130102567A1

  公开（公告）日：2013-04-25

  This invention discloses 3-desoxy-2-methylene-vitamin D analogs, and specifically (20S)-3-desoxy-1α,25-dihydroxy-2-methylene-vitamin D 3 and (20R)-3-desoxy-1α, 25-dihydroxy-2-methylene-vitamin D 3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to monocytes thus evidencing use as anti-cancer agents especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also exhibit relatively high calcemic activity evidencing use in the treatment of bone diseases.

  本发明公开了3-脱氧-2-亚甲基-维生素D类似物，尤其是(20S)-3-脱氧-1α,25-二羟基-2-亚甲基-维生素D3和(20R)-3-脱氧-1α,25-二羟基-2-亚甲基-维生素D3以及其医药用途。这些化合物具有相对较高的结合活性和显著抑制未分化细胞增殖并诱导其向单核细胞分化的活性，因此可用作抗癌剂，特别用于治疗或预防骨肉瘤、白血病、结肠癌、乳腺癌、皮肤癌或前列腺癌。这些化合物还具有相对较高的钙调活性，可用于治疗骨骼疾病。
• LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3
  申请人：Saha Uttam

  公开号：US20090082317A1

  公开（公告）日：2009-03-26

  The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.

  本发明提供了一种新颖的1,25-二羟基维生素D3的16,23-二烯-25-氧基醚类似物，包括含有这些化合物的组合物以及将这些化合物用作CYP24抑制剂的方法。特别是，本发明的这种新颖化合物对于治疗受益于调节1,25-二羟基维生素D3水平的疾病是有用的，例如，细胞增殖紊乱。
• [EN] VITAMIN D RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RECEPTEUR DE VITAMINE D
  申请人：LILLY CO ELI

  公开号：WO2004048309A1

  公开（公告）日：2004-06-10

  The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

  本发明涉及一种新颖的、非类固醇的、二芳基化合物，具有维生素D受体（VDR）调节活性，比1a,25二羟基维生素D3更少引起高钙血症。这些化合物可用于治疗骨疾病和牛皮癣。
• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。